Safety and Efficacy Trial of Delamanid for 6 Months in Participants With Multidrug-resistant Tuberculosis

NCT01424670 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

511

Enrollment

INDUSTRY

Sponsor class

Conditions

Multidrug-resistant Tuberculosis

Interventions

DRUG: Delamanid + OBR
DRUG: Placebo + OBR

Sponsor

Otsuka Pharmaceutical Development & Commercialization, Inc.